NCT00018694

Withdrawn

Cholestanol in Humans

US Department of Veterans Affairs Source

Compare

Other study identifiers

Sponsor study identifier

GAST-007-99S

Study Type

interventional

Actual enrollment (reported)

0

Locations

1 country

Sites

1

Timeline

Study Start

October 1999

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2009

Actual (reported)

Study Completion

December 2009

Actual (reported)

Brief Summary

The treatment of cerebrotendinous xanthomatosis an in born error of bile acid synthesis with chenodeoxycholic acid. Patients with this disease over produce cholestanol and bile acid precursors because of the block in synthesis. Replacement with chenodeoxycholic acid shut down abnormal pathway and reduces elevated level of cholestanol and improves the clinical syndrome.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: withdrawn
Actual enrollment (reported): 0 participants
Study completion date: December 2009
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
October 1999
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
July 3, 2001
Actual (reported)
First Posted
July 5, 2001
Actual (reported)
Primary Completion
December 2009
Actual (reported)
Study Completion
December 2009
Actual (reported)

Last Updated: October 14, 2013
Status Verified: October 2013
Last Update Submitted: October 11, 2013

Conditions

Cerebrotendinous Xanthomatosis

Keywords

bile acid synthesischenodeoxycholic acidsterol 27-hydroxylase

Study Arms (1)

Arm 1

OTHER

Drug: Chenodeoxycholic Acid

Interventions

Chenodeoxycholic AcidDrug

Arm 1

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age5 Years - 80 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

Patients with clinical and biochemical findings of cerebrotendinous xanthomatosis. Elevated levels of serum cholestanol and bile acid precursors.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

US Department of Veterans Affairs
US federal agencylead

Study Sites (1)

VA New Jersey Health Care System, East Orange

East Orange, New Jersey, 07018, United States

MeSH Terms

Conditions

Xanthomatosis, Cerebrotendinous

Interventions

Chenodeoxycholic Acid

Condition Hierarchy (Ancestors)

Lipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesXanthomatosis

Intervention Hierarchy (Ancestors)

Deoxycholic AcidCholic Acids

Study Officials

Gerald Salen
VA New Jersey Health Care System, East Orange
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NON RANDOMIZED
Masking: NONE
Sponsor Type: FED
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 3, 2001

First Posted

July 5, 2001

Study Start

October 1999

Date type not reported

This date has not been verified as actual or estimated.

Withdrawn

NCT00912301

Cheno Effect on Transit in Health and IBS-C

Phase 2Completed

NCT03584893

The Prevalence of CTX Disorder in Juvenile Cataract Cases in Turkey

Unknown

NCT00004442

Study of Bile Acids in Patients With Peroxisomal Disorders

Not ApplicableTerminated

NCT04218006

A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX)

Unknown

NCT03168555

Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy

Phase 4Completed

NCT00465751

Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

Early Phase 1Completed

Bile Acids and Salts

Steroids

Fused-Ring Compounds

Polycyclic Compounds

Cholanes

Primary Completion

December 2009

Actual (reported)

Study Completion

December 2009

Actual (reported)

Last Updated

October 14, 2013

Record last verified: 2013-10

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00018694
Data provider: ClinicalTrials.gov
Source updated: 2013-10-14
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:36:03 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Study Arms (1)

Arm 1

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations